Evidence map›Paper›PMID 30386720›Full record

ArticleRespiratory medicine case reports2018

Occult ovarian clear-cell carcinoma diagnosed as primary adenocarcinoma of the lung: A case report of a diagnostic pitfall for clinicians and pathologists.

Terufumi Kubo, Yoshihiko Hirohashi, Hiromi Fujita, Shintaro Sugita, Yasuhiro Kikuchi, Tomoyo Shinkawa, Munehide Nakatsugawa, Mitsuhiro Tsujiwaki, Yuta Sudo, Yuichiro Asai and 4 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Napsin A Expression in Human Tumors and Normal Tissues.Pathology oncology research : POR · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Terufumi KuboDepartment of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.
Yoshihiko HirohashiDepartment of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.
Hiromi FujitaDepartment of Surgical Pathology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8543, Japan.
Shintaro SugitaDepartment of Surgical Pathology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8543, Japan.
Yasuhiro KikuchiDepartment of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.
Tomoyo ShinkawaDepartment of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.
Munehide NakatsugawaDepartment of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.
Mitsuhiro TsujiwakiDepartment of Surgical Pathology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8543, Japan.
Yuta SudoDepartment of Respiratory Medicine and Allergology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8543, Japan.
Yuichiro AsaiDepartment of Respiratory Medicine and Allergology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8543, Japan.
Yasuaki UmedaDepartment of Respiratory Medicine and Allergology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8543, Japan.
Hiroki TakahashiDepartment of Respiratory Medicine and Allergology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8543, Japan.
Tadashi HasegawaDepartment of Surgical Pathology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8543, Japan.
Toshihiko TorigoeDepartment of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.
Sapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a case of ovarian clear-cell carcinoma that was initially diagnosed as adenocarcinoma of lung origin. This is an instructive diagnostic pitfall for clinicians and pathologists because of the unusual clinical course, small biopsy material, and noteworthy immunophenotype of the carcinoma. Imaging analysis identified only lung and liver lesions. In addition, the biopsy specimen from the lung was TTF-1 negative and napsin A positive, which is still possible for cancer of lung origin. Postmortem examination found that the cancer should be classified as ovarian clear-cell carcinoma distinguished by positive staining for napsin A and paired-box gene 8 (PAX8). Although PAX8 may not be usually investigated when tumoral lesions are identified in only the lung and liver, it is important to keep the necessity of PAX8 in mind to excluding carcinoma of Müllerian, renal, or thyroid origin.

Indexed as

Adenocarcinoma of lungNapsin AOccult cancerOvarian clear-cell carcinoma

Identifiers

PMID30386720
PMCPMC6205346
OpenAlexW2897096677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.